Odimma Therapeutics is the winner of the Start-up Slams organized during BioFIT 2022, a leading partnering event in Europe for technology transfer, academia-industry collaborations, innovation deals in biotech lifesciences. Odimma Therapeutics was recognized as the most innovative project in Europe and had the chance to receive the Merck Group's special prize.
About Odimma Therapeutics
Odimma Therapeutics (Strasbourg – France) is a European biotech company with a unique approach in active personalized cancer immunotherapy. By harnessing the ability of the patient’s own immune system to specifically recognize specific markers displayed by the tumor, also called neoantigens, Odimma Therapeutics has designed a potent next-generation precision immunotherapy platform able induce a powerful cellular immune response against specific tumours markers as well as a strong anti-tumoral effect in several aggressive models such as melanoma, colorectal and breast cancer. By design the personalized product can be produced in a short period of time with a favourable economic profile, with no limits in the number of neoantigens to be targeted thus maximise patient benefit.
To follow our news, you can also connect to our Linkedin page: